PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, B-Cell
- Interventions
- Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisoneDrug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 103
- Registration Number
- NCT01055496
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Rainier Physicians, PC, Puyallup, Washington, United States
Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Device: Heatwrap 1
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 169
- Registration Number
- NCT01055262
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT01054222
- Locations
- 🇵🇹
Hospital Ordem do Carmo, Porto, Portugal
🇵🇹Hospital de São João, Porto, Portugal
🇵🇹Centro de Avaliação Geriátrica, Lisboa, Portugal
Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Phase 4
Completed
- Conditions
- Acute Back Strain
- Interventions
- Drug: FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 123
- Registration Number
- NCT01054820
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
Completed
- Conditions
- Parkinson's DiseaseHyperprolactinemia
- Interventions
- Other: Retrospective study-
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86939
- Registration Number
- NCT01052948
A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ActiveDrug: Placebo
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01051232
- Locations
- 🇯🇵
Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan
Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01050751
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Completed
- Conditions
- Post Menopausal Women With Early Breast Cancer
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2010-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 980
- Registration Number
- NCT01050634
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 206
- Registration Number
- NCT01047358
- Locations
- 🇰🇷
Yeung Nam University Hospital, Daegu, Korea, Republic of
🇰🇷Soon Chun Hyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, Korea, Republic of
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2012-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 503
- Registration Number
- NCT01046903